Pasar al contenido principal

PROLIFERACION Y DIFERENCIACION CELULAR: MECANISMOS Y RELEVANCIA PATOLOGICA

RED2024-153635-T

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Transferencia y Colaboración
Subprograma Subprograma Estatal para impulsar la Colaboración en y entre los Sectores Público y Privado
Convocatoria Redes Investigación /Redes Excelencia
Año convocatoria 2024
Plan Estatal 2024-2027 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Artificial Intelligence in Tumor Evolution: Understanding Cancer Complexity Through Multi-Modal Data Integration in Precision Oncology

  • Espinosa-Sánchez, Asunción
  • Carnero, Amancio
This article belongs to the Special Issue The Artificial Intelligence to the Rescue of Cancer Research, Cancer research has undergone a fundamental transformation in recent decades due to the integration of artificial intelligence (AI) models into the study of tumor biology. However, tumor evolution, driven by genetic and phenotypic alterations leading to heterogeneity, resistance and metastasis, remains a major challenge in oncology. To understand these processes is crucial for developing effective therapeutic strategies and improving patient outcomes. Conventional methods often fail to capture the complexity and dynamics of these processes. In contrast, AI tools have the ability to integrate and analyze large-scale multi-omics, imaging and clinical data, offering the capability to decode tumor complexity. AI-driven methods facilitate multi-modal data integration, enabling the recognition of patterns that connect molecular alterations with phenotypic outcomes. In functional genomics, AI tools predict the effects of genetic variants, identify regulatory elements and map dysregulated pathways, thus clarifying mechanisms underlying tumor development and resistance. In the imaging field, deep learning techniques improve tumor segmentation, characterization and longitudinal monitoring, providing more accurate insights into tumor progression and treatment response. Predictive modeling could allow the anticipation of tumor evolution and drug response, supporting adaptive therapeutic plans and real-time treatment adjustments. Moreover, AI supports biomarker discovery, patient stratification and decision support systems that can improve clinical trial design and accelerate the development of personalized therapies. However, these advances raise important ethical challenges, including data privacy, algorithmic bias and the preservation of patient autonomy. Addressing these concerns is essential to ensure the responsible deployment of AI in oncology., This research was supported by grants from Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I + D + I 2018, Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): PID2024-155394OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, by the “European Union”; AEI-MICIU/FEDER (iDIFFER network RED2024-153635-T). Additional grants from CIBER de Cáncer (CB16/12/00275), from competitive research projects call within the scope of PAIDI 2020—80% co-financed by the European Regional Development Fund (ERDF) from the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities. Junta de Andalucía (DGP_PIDI_2024_00907). Special thanks to the AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR. This research work was funded by the European Commission—NextGenerationEU, through the Momentum CSIC Program: Develop Your Digital Talent. AES, staff hired under the Generation D initiative, promoted by Red.es, an organization attached to the Ministry for Digital Transformation and the Civil Service, for the attraction and retention of talent through grants and training contracts, financed by the Recovery, Transformation and Resilience Plan through the European Union’s Next Generation funds., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

HOOK2 downregulation compromises the tumorigenic and stemness properties of ovarian cancer cells by increasing endoplasmic reticulum stress

  • Suarez-Martinez, Elisa
  • Espinosa-Sánchez, Asunción
  • Piersma, Sander R.
  • Pham, Thang V.
  • Bijnsdorp, Irene V.
  • Jimenez, Connie R.
  • Carnero, Amancio
[Data availability] All data and materials will be available upon reasonable request. Raw proteomics data can be downloaded from the ProteomXchange repository (dataset identifier PXD050782)., Ovarian cancer stands out as one of the tumors with a high mortality rate in women. Therefore, the search for new therapeutic targets is essential to enhance patient prognosis. There is evidence suggesting that HOOK2, an adaptor protein involved in microtubule transport, may play a role in cancer, particularly ovarian cancer. This study examines the role of HOOK2 in the progression of ovarian tumors. The findings reveal that a decrease in HOOK2 levels leads to diminished growth and cellular migration in ovarian cancer cells, impeding the in vivo formation of tumors. The reduction of HOOK2 is associated with both an increase in endoplasmic reticulum stress and an elevation in cell death, the latter likely caused by the activation of the unfolded protein response. Moreover, the study observes that the decrease in HOOK2 diminishes the properties of cancer stem cells in ovarian cancer, possibly due to the increase in cell death specifically found within these stem cells. Given the profound impact of reduced HOOK2 levels on ovarian cancer cells, this gene emerges as a promising therapeutic strategy for treating ovarian cancer patients., This research was supported by grants from Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I + D + I 2018, Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): PID2024-155394OB-I00 and PID2021-122629OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, by the “European Union”; AEI-MICIU/FEDER (RED2024-153635-T (iDIFFER network)). Additional grants from CIBER de Cáncer (CB16/12/00275), from Consejería de Economía, Conocimiento, Empresas y Universidad de la Junta de Andalucía (DGP_PIDI_2024_00907), co-financed by the European Regional Development Fund (ERDF) (Junta de Andalucía). AE-S was hired under the Generation D initiative, promoted by Red.es, an organization attached to the Ministry for Digital Transformation and the Civil Service, for the attraction and retention of talent through grants and training contracts, financed by the Recovery, Transformation and Resilience Plan through the European Union’s Next Generation funds. Special thanks to the AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR for supporting this work., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Role of WDR66 in Stemness, Therapy Resistance and Tumor microenvironment modulation in Head and Neck Cancer

  • Sánchez-Díaz, Laura
  • Espinosa-Sánchez, Asunción
  • Carnero, Amancio
Head and neck cancer comprises a variety of malignant tumors affecting regions such as the oral cavity, pharynx, larynx, paranasal sinuses, nasal cavity and salivary glands. These tumors are highly heterogeneous, making it difficult to identify specific biomarkers and effective treatments, increasing mortality and recurrence rates. Databases analyzed to identify genes with altered expression in tumor tissue showed WDR66 able predict prognosis and survival, in HNSCC, but whose involvement in tumorigenesis is unknown. High WDR66 expression was associated with a worse prognosis, although its overexpression did not significantly alter basic tumor properties in cancer cells in vitro or in vivo. However, we observed an increase in pluripotency factors (OCT3/4, SOX2, KLF4, LIN28), resistance to chemotherapies and a decrease in apoptosis. Consistently, decreasing WDR66 expression using CRISPR showed a reduction in tumorsphere formation, lower expression of pluripotency-related genes, decreased cell migration, and increased sensitivity to cisplatin. These effects were more pronounced in vivo, suggesting a relevant role of WDR66 in the tumor microenvironment. The medium conditioned by cells overexpressing WDR66 promoted migration, maintained the stem cell phenotype, and inhibited immune differentiation, harboring soluble factors involved in progression and metastasis. In this media, we identified several cytokines and growth factors related to inflammation and immune system modulation. In conclusion, WDR66 emerges as a potential biomarker of poor prognosis and a possible predictor of response to immunotherapy, given its impact on cellular pluripotency, treatment resistance and modification of the tumor microenvironment in head and neck cancer., This research was supported by grants from Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I+D+I 2018, Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): PID2021-122629OB-I00 and PID2024-155394OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, by the “European Union”; AEI-MICIU/FEDER (iDIFFER network RED2024-153635-T). Additional grants from CIBER de Cáncer (CB16/12/00275), from competitive research projects call within the scope of PAIDI 2020—80% co-financed by the European Regional Development Fund (ERDF) from the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities. Junta de Andalucía (DGP_PIDI_2024_00907). Special thanks to the AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR. AE-S staff hired under the Generation D initiative, promoted by Red.es, an organization attached to the Ministry for Digital Transformation and the Civil Service, for the attraction and retention of talent through grants and training contracts, financed by the Recovery, Transformation and Resilience Plan through the European Union's Next Generation funds., Peer reviewed, Modelo experimental animal
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tumoral switch in NUMB splicing changes essential transcription pathways and induces malignant properties in tumour cells

  • García-Heredia, J. M.
  • Ortega-Campos, Sara M.
  • Carnero, Amancio
[Data availability] Availability of data and materials All datasets analysed in this study are publicly available. Breast cancer datasets from the Gene Expression Omnibus (GEO, RRID:SCR_005012), including GSE69031, GSE21653, GSE1456, GSE20685, GSE25066, GSE42568, GSE162228, and GSE12093, were used in this study and are publicly available at GEO [78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93]. TCGA-BRCA RNA-seq isoform expression and clinical data were obtained from the NCI Genomic Data Commons (GDC; RNA-seq Level 3 RSEM isoform-normalized data dated 2015–08-06). CCLE expression data were obtained from the Cancer Cell Line Encyclopedia (CCLE; RNA-seq transcript TPM file dated 2018–09-29), and drug-response data were integrated with GDSC (release dated 2023–10-27) after harmonising cell-line identifiers. Breast PDX isoform quantifications and metadata were obtained from the PDMR resource. Key analysis outputs and sample-level annotations, including transcript-level differential expression, pathway enrichment results, metabolic expression matrices, drug-response statistics, and NUMB-score assignments, are provided in the Supplementary Information files (Additional file 3: Tables S2–S10). All custom scripts used for data processing and analysis are publicly available at GitHub (https://github.com/jmgheredia/NUMB-tumoral-switch) and are distributed under an OSI-compliant open-source license (MIT License) [111]. The source code has also been permanently archived in Zenodo with an assigned DOI (https://doi.org/10.5281/zenodo.18522980) [112]., [Background] Emerging evidence indicates that cancer is associated with widespread splicing alterations that generate tumour-specific isoforms. One example is NUMB, an evolutionarily conserved adaptor protein, which produces four isoforms (p72, p71, p66, and p65) through alternative splicing of exons 3 and 9. Although traditionally considered as a tumour suppressor, NUMB has also been reported as an oncogene. We propose that this dual role reflects isoform-specific expression., [Results] Using public databases, we identify a tumour-associated switch in NUMB isoform expression: p72 and p71 are upregulated in tumours, whereas p66 and p65 are more highly expressed in non-tumour tissues. These isoforms show distinct associations with key cellular processes. NUMBL, a NUMB homolog, displays expression patterns similar to p65. We further identify two transcriptional clusters: one characterised by high expression of p72 and p71, and the other by enhanced p66/p65/NUMBL expression. These clusters exhibit differential associations with Notch, WNT/β-catenin, Hedgehog, and Hippo signalling pathways, suggesting isoform-specific regulatory roles. In breast cancer cell lines, we develop a NUMB-score based on isoform expression, which classifies cell lines into biologically distinct groups. The p72/p71-enriched group shows distinct signatures, pathway activity, and drug sensitivity. Application of this score to TCGA-BRCA samples reveals a significant link between high NUMB-score and poor survival, as confirmed by Kaplan–Meier analysis., [Conclusions] We find that NUMB emerges as a potential oncogenic contributor and biomarker in the context of splicing-based precision oncology, highlighting Isoform-specific expression as a clinical determinant of tumour behaviour, pathway activity, and therapeutic response., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This research was supported by grants from Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I + D + I 2018, Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): PID2024-155394OB-I00 and PID2021-122629OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, by the “European Union”; AEI-MICIU/FEDER (iDIFFER network: RED2024-153635-T). Additional grants from CIBER de Cáncer (CB16/12/00275), from Consejeria de Salud (PI-0397–2017) and Projects P18-RT-2501; and DGP_PIDI_2024_00907 from the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities. Junta de Andalucía. Special thanks to the AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR for supporting this work., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

miR-203 facilitates timely cell fate transitions via epigenetic modulation during early embryogenesis

  • González-Martínez, José
  • Sánchez-Belmonte, Agustín
  • Ayala, Estefanía
  • Escobar Rodriguez, Beatriz
  • Gómez Alonso, Jesús
  • Garcia Diaz, Alejandro
  • Nogueira, Enrique
  • Malumbres, Marcos
Epigenetic; Embryogenesis, Epigenètica; Embriogènesi, Epigenética; Embriogénesis, Commonly expressed at developmental transitions, microRNAs operate as fine-tuners of gene expression to facilitate cell fate acquisition and lineage segregation. Nevertheless, how they might regulate the earliest developmental transitions in early mammalian embryogenesis remains obscure. Here, in a strictly in vivo approach based on genetically engineered mouse models and single-cell RNA sequencing, we identify microRNA-203 (miR-203) as a critical regulator of timely progression in preimplantation mouse embryos. Genetically engineered mouse models including a generated embryonic reporter (early embryo reporter) transgenic mouse carrying murine endogenous retrovirus-L (MERVL)–Tomato and SRY-box 2 (Sox2)–green fluorescent protein transgenes show that loss of miR-203 slows down early preimplantation development leading to the accumulation of embryos with high expression of totipotency-associated markers, including MERVL endogenous retroviral elements. A combination of single-cell transcriptional studies and epigenetic analyses identified histone acetylases including the central coactivator and histone acetyltransferase EP300 as critical miR-203 targets in the control of cell specification in early embryos. These data suggest that miR-203 carves the epigenetic rewiring required for early developmental transitions, allowing a timely and correctly paced development, at least partially by fine-tuning EP300 levels., A.S.-B. and E.N. were supported by FPI (PRE2022-103179) and FPU (FPU2022-02792) contracts from the Spanish Ministry of Science and Innovation (MICINN). A.G.-D. received a predoctoral contract from the “la Caixa” Foundation (LCF/BQ/DI21/11860054). M.M. laboratory was supported by research grants from MICINN/AEI/FEDER [PID2021-128726, PDC2022-133408-I00, RED2024-153635-T (iDIFFER), and PID2024-161681OB-10] and Comunidad de Madrid (Y2020/BIO-6519 and S2022/BMD-7437). This research was supported by CIBER–Consorcio Centro de Investigación Biomédica en Red (CIBERONC), Instituto de Salud Carlos III, MICINN. VHIO would like to acknowledge the Cellex Foundation for providing research facilities and equipment and the CERCA Program from the Generalitat de Catalunya for support on this research. CNIO (CEX2019-000891-S) and VHIO (CEX2020-001024-S/AEI/10.13039/501100011033) are Centers of Excellence Severo Ochoa (Agencia Estatal de Investigación, MICINN).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

miR-203 facilitates timely cell fate transitions via epigenetic modulation during early embryogenesis

  • González-Martínez, José
  • Sánchez-Belmonte, Agustín
  • Ayala, Estefanía
  • Escobar Rodriguez, Beatriz
  • Gómez Alonso, Jesús
  • Garcia Diaz, Alejandro
  • Nogueira, Enrique
  • Malumbres, Marcos
Epigenetic; Embryogenesis, Epigenètica; Embriogènesi, Epigenética; Embriogénesis, Commonly expressed at developmental transitions, microRNAs operate as fine-tuners of gene expression to facilitate cell fate acquisition and lineage segregation. Nevertheless, how they might regulate the earliest developmental transitions in early mammalian embryogenesis remains obscure. Here, in a strictly in vivo approach based on genetically engineered mouse models and single-cell RNA sequencing, we identify microRNA-203 (miR-203) as a critical regulator of timely progression in preimplantation mouse embryos. Genetically engineered mouse models including a generated embryonic reporter (early embryo reporter) transgenic mouse carrying murine endogenous retrovirus-L (MERVL)–Tomato and SRY-box 2 (Sox2)–green fluorescent protein transgenes show that loss of miR-203 slows down early preimplantation development leading to the accumulation of embryos with high expression of totipotency-associated markers, including MERVL endogenous retroviral elements. A combination of single-cell transcriptional studies and epigenetic analyses identified histone acetylases including the central coactivator and histone acetyltransferase EP300 as critical miR-203 targets in the control of cell specification in early embryos. These data suggest that miR-203 carves the epigenetic rewiring required for early developmental transitions, allowing a timely and correctly paced development, at least partially by fine-tuning EP300 levels., A.S.-B. and E.N. were supported by FPI (PRE2022-103179) and FPU (FPU2022-02792) contracts from the Spanish Ministry of Science and Innovation (MICINN). A.G.-D. received a predoctoral contract from the “la Caixa” Foundation (LCF/BQ/DI21/11860054). M.M. laboratory was supported by research grants from MICINN/AEI/FEDER [PID2021-128726, PDC2022-133408-I00, RED2024-153635-T (iDIFFER), and PID2024-161681OB-10] and Comunidad de Madrid (Y2020/BIO-6519 and S2022/BMD-7437). This research was supported by CIBER–Consorcio Centro de Investigación Biomédica en Red (CIBERONC), Instituto de Salud Carlos III, MICINN. VHIO would like to acknowledge the Cellex Foundation for providing research facilities and equipment and the CERCA Program from the Generalitat de Catalunya for support on this research. CNIO (CEX2019-000891-S) and VHIO (CEX2020-001024-S/AEI/10.13039/501100011033) are Centers of Excellence Severo Ochoa (Agencia Estatal de Investigación, MICINN).